Thermo Fisher Scientific (NYSE:TMO) Stock Rating Upgraded by Royal Bank Of Canada

Key Points

• Royal Bank of Canada upgraded Thermo Fisher Scientific to a hold rating, adding to a mixed but generally positive analyst backdrop for the stock.
• The company reported better-than-expected Q1 earnings of $5.44 per share on $11.01 billion in revenue, with revenue up 6.2% year over year.
• TMO shares were trading at $438.16, well below the consensus price target of $616.10, while analysts overall maintain a Moderate Buy rating.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) was upgraded by Royal Bank Of Canada to a "hold" rating in a research report issued on Thursday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on TMO. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating for the company in a research note on Friday, April 24th. Jefferies Financial Group upgraded Thermo Fisher Scientific to a "strong-buy" rating in a research note on Friday, April 24th. Weiss Ratings reiterated a "hold (c)" rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research note on Friday, May 8th. Finally, Barclays reduced their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating for the company in a research note on Tuesday, April 14th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $616.10.

Thermo Fisher Scientific Price Performance

TMO stock opened at $438.16 on Thursday. The business has a 50 day moving average price of $486.00 and a 200 day moving average price of $542.12. The stock has a market cap of $162.83 billion, a price-to-earnings ratio of 24.09, a PEG ratio of 1.98 and a beta of 0.88. Thermo Fisher Scientific has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion during the quarter, compared to analysts' expectations of $10.86 billion. During the same quarter in the previous year, the business earned $5.15 earnings per share. The firm's revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts anticipate that Thermo Fisher Scientific will post 24.86 earnings per share for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares of the company's stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Assetmark Inc. grew its holdings in Thermo Fisher Scientific by 22.9% in the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company's stock valued at $21,819,000 after purchasing an additional 7,023 shares during the last quarter. Cornerstone Investment Partners LLC acquired a new stake in Thermo Fisher Scientific in the third quarter valued at $41,393,000. Mackenzie Financial Corp grew its holdings in Thermo Fisher Scientific by 29.4% in the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company's stock valued at $134,130,000 after purchasing an additional 62,790 shares during the last quarter. VELA Investment Management LLC boosted its stake in shares of Thermo Fisher Scientific by 65.5% during the third quarter. VELA Investment Management LLC now owns 9,305 shares of the medical research company's stock valued at $4,513,000 after acquiring an additional 3,683 shares during the last quarter. Finally, NEOS Investment Management LLC boosted its stake in shares of Thermo Fisher Scientific by 28.6% during the third quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company's stock valued at $24,913,000 after acquiring an additional 11,415 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.